Abstract
Cerebral malaria a severe complication of an infection caused by the parasite Plasmodium falciparum. It is an acute encephalopathy and currently the adjunctive therapy supporting the anti-malarial treatment consists of glucose and oxygen supplementation. Wishing to improve the adjunctive therapy, we have studied the use of erythropoietin (EPO) and its possible neuroprotective effects in a murine model of cerebral malaria. EPO reduces the mortality and neuropathology in this model and is well tolerated. Our research is discussed in relation to the current literature and the potential as using EPO as adjunct therapy in humans is discussed.
Keywords: Cerebral malaria, Plasmodium, murine models, erythropoietin, adjunctive therapy, inflammation, hypoxia, neuropathology, neuroregeneration.
Related Journals
Current Drug Safety
Inflammation & Allergy - Drug Targets (Discontinued)
Recent Patents on Anti-Infective Drug Discovery
Current Drug Discovery Technologies
Current Drug Targets - Inflammation & Allergy
Current Bioactive Compounds
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Anti-Cancer Agents in Medicinal Chemistry
Current Drug Targets
Letters in Drug Design & Discovery
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development